{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:15:23Z","timestamp":1761884123887,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.reumae.2021.03.005","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T02:08:22Z","timestamp":1631758102000},"page":"331-337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characteristics of patients with immune-mediated inflammatory diseases hospitalized for SARS-CoV-2 infection"],"prefix":"10.1016","volume":"18","author":[{"given":"Montserrat","family":"Robustillo-Villarino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"\u00c1lvarez-Arroyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Javier","family":"Carrera-Hueso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e9s","family":"Barreda-Altaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Nieto-Cid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Mar\u00eda","family":"Girona-Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"El-Qutob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reumae.2021.03.005_bib0005","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jbspin.2020.03.010","article-title":"Implications of COVID-19 for the management of patients with inflammatory rheumatic diseases","volume":"87","author":"Richez","year":"2020","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.reumae.2021.03.005_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102523","article-title":"COVID-19 infection and rheumatoid arthritis: Faraway, so close!","volume":"19","author":"Favalli","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.reumae.2021.03.005_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2020.104361","article-title":"The clinical course and its correlated immune status in COVID-19 pneumonia","volume":"127","author":"He","year":"2020","journal-title":"J Clin Virol"},{"key":"10.1016\/j.reumae.2021.03.005_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality","volume":"55","author":"Zhang","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.reumae.2021.03.005_bib0025","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.medmal.2020.04.002","article-title":"Interleukin-6 as a potential biomarker of COVID-19 progression","volume":"50","author":"Ulhaq","year":"2020","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.reumae.2021.03.005_bib0030","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2021.03.005_bib0035","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMc2009567","article-title":"Covid-19 in immune-mediated inflammatory diseases \u2014 case series from New York","volume":"383","author":"Haberman","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2021.03.005_bib0040","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/annrheumdis-2020-217948","article-title":"Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies","volume":"79","author":"Sanchez-Piedra","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.03.005_bib0045","doi-asserted-by":"crossref","first-page":"102502","DOI":"10.1016\/j.jaut.2020.102502","article-title":"SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: a cross-sectional study on 916 patients","author":"Zen","year":"2020","journal-title":"J Autoimmun"},{"key":"10.1016\/j.reumae.2021.03.005_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102575","article-title":"SARS-CoV-2 infection among patients with systemic autoimmune diseases","volume":"19","author":"Emmi","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.reumae.2021.03.005_bib0055","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.semarthrit.2020.05.001","article-title":"Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs","volume":"50","author":"Michelena","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.reumae.2021.03.005_bib0060","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"79","author":"Gianfrancesco","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.03.005_bib0065","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jbspin.2020.05.003","article-title":"Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: a population-based study in the first two months of COVID-19 outbreak in Italy","volume":"87","author":"Quartuccio","year":"2020","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.reumae.2021.03.005_bib0070","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1136\/annrheumdis-2020-217763","article-title":"Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases","volume":"79","author":"Pablos","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.03.005_bib0075","unstructured":"Centers for disease control and prevention (CDC). Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/need-extra-precautions\/pregnancy-breastfeeding.html. [Accessed 10 January 2021]."},{"key":"10.1016\/j.reumae.2021.03.005_bib0080","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s00296-020-04698-y","article-title":"Coronavirus disease 2019 (COVID-19) during pregnancy in patients with rheumatic diseases","volume":"40","author":"Boyadzhieva","year":"2020","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.reumae.2021.03.005_bib0085","unstructured":"European Centre for Disease Prevention and Control (ECDC). Available from: https:\/\/www.ecdc.europa.eu\/en\/covid-19\/surveillance\/case-definition. [Accessed 10 January 2021]."},{"key":"10.1016\/j.reumae.2021.03.005_bib0090","unstructured":"Asociaci\u00f3n espa\u00f1ola de medicamentos y productos sanitarios (AEMPS). Available from: https:\/\/www.aemps.gob.es\/la-aemps\/ultima-informacion-de-la-aemps-acerca-del-covid-19\/tratamientos-disponibles-para-el-manejo-de-la-infeccion-respiratoria-por-sars-cov-2\/. [Accessed 10 January 2021]."},{"key":"10.1016\/j.reumae.2021.03.005_bib0095","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40620-020-00881-3","article-title":"The impact of COVID-19 pandemic on patients with ANCA associated vasculitis","volume":"34","author":"Kant","year":"2021","journal-title":"J Nephrol"},{"key":"10.1016\/j.reumae.2021.03.005_bib0100","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/annrheumdis-2020-217424","article-title":"Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies","volume":"79","author":"Monti","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.03.005_bib0105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13063-020-04999-4","article-title":"Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial","volume":"22","author":"Les Bujanda","year":"2021","journal-title":"Trials."},{"key":"10.1016\/j.reumae.2021.03.005_bib0110","first-page":"1","article-title":"Methylprednisolone in adults hospitalized with COVID-19 pneumonia: an open-label randomized trial (GLUCOCOVID)","author":"Corral-Gudino","year":"2021","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.reumae.2021.03.005_bib0115","doi-asserted-by":"crossref","first-page":"623","DOI":"10.7326\/M20-4207","article-title":"Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial","volume":"173","author":"Skipper","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.reumae.2021.03.005_bib0120","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3899\/jrheum.091461","article-title":"Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities","volume":"85","author":"El-Gabalawy","year":"2010","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.reumae.2021.03.005_bib0125","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/jmv.26237","article-title":"Obesity aggravates COVID-19: a systematic review and meta-analysis","volume":"93","author":"Yang","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.reumae.2021.03.005_bib0130","unstructured":"Sociedad espa\u00f1ola de reumatolog\u00eda (SER). Available from: https:\/\/www.ser.es\/el-coronavirus-covid-19-y-los-pacientes-con-enfermedades-reumaticas\/. [Accessed January 10 2021]."},{"key":"10.1016\/j.reumae.2021.03.005_bib0135","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.reuma.2020.06.011","article-title":"Recommendations on the management of adult patients with rheumatic diseases in the context of SARS-CoV-2\/COVID-19 infection. Colombian Association of Rheumatology","volume":"16","author":"Saldarriaga Rivera","year":"2020","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reumae.2021.03.005_bib0140","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/art.41388","article-title":"Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data?","volume":"72","author":"Favalli","year":"2020","journal-title":"Arthritis Rheumatol"}],"container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574321001611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574321001611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:02:48Z","timestamp":1761879768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173574321001611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2173574321001611"],"URL":"https:\/\/doi.org\/10.1016\/j.reumae.2021.03.005","relation":{},"ISSN":["2173-5743"],"issn-type":[{"type":"print","value":"2173-5743"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics of patients with immune-mediated inflammatory diseases hospitalized for SARS-CoV-2 infection","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reumae.2021.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.reuma.2021.03.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Reumatolog\u00eda y Colegio Mexicano de Reumatolog\u00eda. All rights reserved.","name":"copyright","label":"Copyright"}]}}